{"id":17895,"date":"2026-01-28T20:20:45","date_gmt":"2026-01-28T12:20:45","guid":{"rendered":"https:\/\/y2nbc5qg9c-staging.wpdns.site\/planting-the-flag-of-asean-evergreen-forms-alliance-with-sbc-malaysia\/"},"modified":"2026-10-22T15:22:15","modified_gmt":"2026-10-22T07:22:15","slug":"planting-the-flag-of-asean-evergreen-forms-alliance-with-sbc-malaysia","status":"publish","type":"post","link":"https:\/\/u-neuron.com\/en\/planting-the-flag-of-asean-evergreen-forms-alliance-with-sbc-malaysia\/","title":{"rendered":"Expanding into ASEAN: U-NEURON Partners with Malaysia&#8217;s SBC"},"content":{"rendered":"&#13;\n<h2 class=\"wp-block-heading\">\u00a0<\/h2>&#13;\n&#13;\n<h2 class=\"wp-block-heading\">Collaborating on Amniotic Fluid Stem Cell Clinical Applications and Research; Full Line of Nutritional Products Scheduled for Market Launch in 2025<\/h2>&#13;\n&#13;\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"768\" class=\"wp-image-17175\" src=\"https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/01\/b1f102fa471c5d8a0546e9bcf769284d-1.jpg\" alt=\"\" title=\"\" srcset=\"https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/01\/b1f102fa471c5d8a0546e9bcf769284d-1.jpg 1024w, https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/01\/b1f102fa471c5d8a0546e9bcf769284d-1-400x300.jpg 400w, https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/01\/b1f102fa471c5d8a0546e9bcf769284d-1-768x576.jpg 768w, https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/01\/b1f102fa471c5d8a0546e9bcf769284d-1-430x323.jpg 430w, https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/01\/b1f102fa471c5d8a0546e9bcf769284d-1-700x525.jpg 700w, https:\/\/u-neuron.com\/wp-content\/uploads\/2026\/01\/b1f102fa471c5d8a0546e9bcf769284d-1-150x113.jpg 150w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption><\/figcaption><\/figure>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Expanding into ASEAN: U-NEURON Partners with Malaysia&#8217;s SBC\nU-NEURON Biomedical signs a Memorandum of Understanding (MOU) with the Sarawak Biodiversity Centre (SBC) in Malaysia. (Photo courtesy of the company)<\/p>&#13;\n&#13;\n<h3 class=\"wp-block-heading\">U-NEURON Biomedical (6973) announced its entry into the ASEAN market on December 16. Chairman Dr. Frank Chien stated that the company has signed a Memorandum of Understanding (MOU) with the Sarawak Biodiversity Centre (SBC) in Malaysia. Using Sarawak as a regional hub, both parties will collaborate on clinical applications and research related to amniotic fluid stem cells. Additionally, the company will introduce a new series of nutritional supplements featuring velvet antler as the primary ingredient, with a full product launch slated for 2025.<\/h3>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">In the first 11 months of this year, U-NEURON reported revenue of NT$41 million\u2014a 79.5% year-on-year increase. Institutional investors anticipate that revenue will cross the NT$100 million threshold next year, driven by four primary growth engines: revenue contributions from the ASEAN market, the distribution and launch of skincare products in Mainland China via Chlitina&#8217;s marketing network, velvet antler stem cell hair-restoration products, and velvet antler health supplements.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Dr. Chien emphasized that U-NEURON is using Malaysia as its beachhead to expand across the ASEAN region, promoting Halal-certified regenerative medicine, cosmetics, and nutritional supplements. Signing the MOU and establishing operations with SBC will not only facilitate joint research on amniotic fluid stem cells but also open the door for local clinical trials, establishing Sarawak as U-NEURON&#8217;s primary hub in Southeast Asia.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Holding global patents for world-first amniotic fluid stem cell culture technology, U-NEURON is currently enrolling patients at two hospitals in Taiwan for UA002, a novel drug designed to treat erectile dysfunction. Phase I safety follow-up is expected to wrap up in the first half of next year, followed by consultations with regulatory authorities on Phase II clinical trial design and plans to file an Investigational New Drug (IND) application in the United States. Meanwhile, its exosome-based candidate UB003 for moderate-to-severe dry eye disease is currently undergoing process development in compliance with international regulations.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">U-NEURON has developed five innovative skincare raw materials that have achieved International Nomenclature of Cosmetic Ingredients (INCI) registration\u2014the highest number among biotechnology companies in Taiwan. Its comprehensive R&amp;D capabilities in stem cell products have earned strong recognition in Malaysia.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Samuel Ting, advisor to Sarawak BEC, noted that through this partnership with U-NEURON, they hope to encourage more private enterprises and the Malaysian government to invest in research on stem cell medical applications, ultimately making costly, novel gene and cell therapies more affordable and accessible to the general public.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Dr. Chien added that to maximize the advantages of its patented amniotic fluid stem cell technology, U-NEURON is launching a brand-new line of velvet antler peptide health foods and velvet antler stem cell skincare products.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Dr. Hsiao-MinHuang, President and Chief Technology Officer of U-NEURON, explained that through proprietary AI extraction technology, U-NEURON has extracted high concentrations of the active factor Activin-A. This breakthrough preserves the core potency of velvet antler while maximizing the multi-functional efficacy of Activin-A, boosting both absorption rates and stability to promote human cell regeneration and functional activation.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Dr. Chien concluded that in addition to partnering with Chlitina Group\u2019s KindShare to expand their reach across the Taiwan Strait aesthetic medicine market, the company is aggressively building its presence in Southeast Asia, projecting multi-fold revenue growth in 2025.<\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">Source:<a href=\"https:\/\/www.ctee.com.tw\/news\/20241217700254-439901\" rel=\"nofollow noopener\" target=\"_blank\">Source:https:\/\/www.ctee.com.tw\/news\/20240104700226-439901<\/a><\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">2024.12.17 Industrial and Commercial Times <a href=\"https:\/\/www.ctee.com.tw\/reporter\/60155\" rel=\"nofollow noopener\" target=\"_blank\">Commercial Times \/ Reporter Hui-Jung Tu (December 17, 2024)<\/a><\/p>&#13;\n&#13;\n<p class=\"wp-block-paragraph\">\u00a0<\/p>&#13;\n","protected":false},"excerpt":{"rendered":"<p>Collaborating on Amniotic Fluid Stem Cell Clinical Applications and Research; Full Line of Nutritional Products Scheduled for Market Launch in 2025<\/p>\n","protected":false},"author":15,"featured_media":17896,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[235,240,243,239,236],"tags":[],"class_list":["post-17895","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investor-zone","category-event-and-exhibition-information","category-international-layout-and-authorization","category-latest-news","category-media-reports"],"acf":[],"_links":{"self":[{"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/posts\/17895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/comments?post=17895"}],"version-history":[{"count":7,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/posts\/17895\/revisions"}],"predecessor-version":[{"id":18255,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/posts\/17895\/revisions\/18255"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/media\/17896"}],"wp:attachment":[{"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/media?parent=17895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/categories?post=17895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/u-neuron.com\/en\/wp-json\/wp\/v2\/tags?post=17895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}